Inhibrx Biosciences IncNASDAQ:INBX
- LAST PRICE15.2200
- TODAY'S CHANGE (%)-0.4400 (-2.8097%)
- Bid / Lots15.2200/ 2
- Ask / Lots15.2900/ 2
- Open / Previous Close15.5600 / 15.6600
- Day Range
- 52 Week Range
- Volume83,614
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INBX |
|---|---|---|
| 09:32 ET | 1233 | 15.56 |
| 09:34 ET | 2250 | 15.4 |
| 09:38 ET | 100 | 15.26 |
| 09:41 ET | 200 | 15.29 |
| 09:43 ET | 100 | 15.36 |
| 09:45 ET | 100 | 15.26 |
| 09:50 ET | 400 | 15.34 |
| 09:54 ET | 100 | 15.27 |
| 09:56 ET | 200 | 15.27 |
| 09:57 ET | 363 | 15.27 |
| 09:59 ET | 100 | 15.33 |
| 10:01 ET | 1596 | 15.545 |
| 10:08 ET | 100 | 15.54 |
| 10:10 ET | 1000 | 15.425 |
| 10:14 ET | 4549 | 15.26 |
| 10:15 ET | 200 | 15.32 |
| 10:17 ET | 2229 | 15.34 |
| 10:19 ET | 200 | 15.37 |
| 10:24 ET | 727 | 15.27 |
| 10:26 ET | 300 | 15.2439 |
| 10:28 ET | 200 | 15.31 |
| 10:30 ET | 400 | 15.31 |
| 10:32 ET | 200 | 15.31 |
| 10:33 ET | 100 | 15.31 |
| 10:35 ET | 200 | 15.31 |
| 10:37 ET | 1829 | 15.3 |
| 10:39 ET | 239 | 15.25 |
| 10:42 ET | 2506 | 15.4297 |
| 10:44 ET | 100 | 15.335 |
| 10:48 ET | 5441 | 15.25 |
| 10:50 ET | 949 | 15.26 |
| 10:51 ET | 1973 | 15.25 |
| 10:53 ET | 3777 | 15.23 |
| 10:55 ET | 500 | 15.25 |
| 10:57 ET | 100 | 15.25 |
| 11:06 ET | 100 | 15.23 |
| 11:08 ET | 1777 | 15.24 |
| 11:11 ET | 400 | 15.24 |
| 11:13 ET | 2282 | 15.24 |
| 11:15 ET | 100 | 15.24 |
| 11:18 ET | 100 | 15.24 |
| 11:22 ET | 100 | 15.11 |
| 11:24 ET | 247 | 15.23 |
| 11:26 ET | 700 | 15.23 |
| 11:27 ET | 1177 | 15.175 |
| 11:31 ET | 1186 | 15.23 |
| 11:33 ET | 200 | 15.24 |
| 11:36 ET | 100 | 15.25 |
| 11:42 ET | 100 | 15.18 |
| 11:44 ET | 800 | 15.29 |
| 11:45 ET | 600 | 15.26 |
| 11:47 ET | 593 | 15.26 |
| 11:49 ET | 200 | 15.25 |
| 11:51 ET | 100 | 15.25 |
| 11:54 ET | 100 | 15.255 |
| 11:58 ET | 100 | 15.24 |
| 12:00 ET | 1201 | 15.3 |
| 12:02 ET | 400 | 15.25 |
| 12:03 ET | 2360 | 15.26 |
| 12:07 ET | 1600 | 15.25 |
| 12:12 ET | 655 | 15.26 |
| 12:14 ET | 900 | 15.29 |
| 12:16 ET | 600 | 15.29 |
| 12:30 ET | 100 | 15.2 |
| 12:34 ET | 1000 | 15.34 |
| 12:38 ET | 1800 | 15.42 |
| 12:39 ET | 400 | 15.28 |
| 12:41 ET | 100 | 15.34 |
| 12:43 ET | 100 | 15.27 |
| 12:48 ET | 100 | 15.23 |
| 12:50 ET | 100 | 15.29 |
| 12:56 ET | 1294 | 15.305 |
| 12:57 ET | 200 | 15.27 |
| 12:59 ET | 500 | 15.25 |
| 01:01 ET | 100 | 15.26 |
| 01:03 ET | 200 | 15.23 |
| 01:12 ET | 100 | 15.24 |
| 01:14 ET | 100 | 15.21 |
| 01:15 ET | 100 | 15.22 |
| 01:19 ET | 100 | 15.22 |
| 01:24 ET | 100 | 15.2 |
| 01:26 ET | 100 | 15.22 |
| 01:32 ET | 100 | 15.2 |
| 01:33 ET | 1550 | 15.202 |
| 01:39 ET | 1440 | 15.29 |
| 01:46 ET | 100 | 15.25 |
| 01:55 ET | 100 | 15.24 |
| 02:02 ET | 100 | 15.25 |
| 02:04 ET | 200 | 15.255 |
| 02:08 ET | 100 | 15.22 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibrx Biosciences Inc | 226.7M | 0.1x | --- |
Fulcrum Therapeutics Inc | 222.8M | -10.3x | --- |
Immutep Ltd | 325.8M | -8.8x | --- |
Omeros Corp | 230.0M | -1.2x | --- |
Gossamer Bio Inc | 223.2M | -2.6x | --- |
Cabaletta Bio Inc | 230.6M | -2.5x | --- |
Company Information
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Contact Information
- Headquarters
- 11025 N. Torrey Pines Road, Suite 140LA JOLLA, CA, United States 92037
- Phone
- 858-795-4220
- Fax
- 302-636-5454
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $226.7M |
|---|---|
Revenue (TTM) | $1.9M |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $121.21 |
Book Value | $0.92 |
P/E Ratio | 0.1x |
Price/Sales (TTM) | 122.3 |
Price/Cash Flow (TTM) | 0.1x |
Operating Margin | 89,188.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
